All In Biotech

Drug Trial Radar · NCT01594970

A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

Last checked: Nov 19, 2026Latest source record: Jan 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

800

Actual

Start

Mar 2012

Primary completion

Jan 2013

Study completion Jan 2013

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
May 9, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).

Conditions

  • Glaucoma, Open-Angle
  • Ocular Hypertension

Interventions

  • Bimatoprost 0.01%Drug

    1 drop in the affected eye(s), administered in the evening for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severity of Ocular Hyperemia in the Study Eye on a 5-Point ScaleTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.